Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2015-01-16 Report Publication Anno…
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a short announcement titled "Onxeo annonce son calendrier financier 2015" (Onxeo announces its 2015 financial calendar). It lists future dates for key events like the release of 2014 consolidated accounts, the Annual General Meeting (AGM), and quarterly revenue updates. Since the document itself is an announcement detailing *when* reports and meetings will occur, rather than being the report itself (like a 10-K or IR), it fits the definition of a Report Publication Announcement (RPA). The length (3247 chars) also supports the 'MENU VS MEAL' rule, indicating it's an announcement rather than a full report.
2015-01-16 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that the CEO of Onxeo will be presenting corporate information at the Biotech Showcase 2015 Conference, which runs parallel to the JP Morgan Healthcare Conference. This is an announcement about participation in an investor event, not the presentation material itself, nor is it a formal regulatory filing like a 10-K or ER. Since it is an announcement regarding an upcoming presentation/event participation, it most closely aligns with Investor Presentation (IP) materials or, more broadly, an announcement about investor relations activities. Given the options, 'Investor Presentation (IP)' is the best fit as it relates to presenting company information to investors, even though this specific text is the announcement of the presentation, not the presentation slides themselves. However, if we strictly follow the 'MENU VS MEAL' rule, this is an announcement about an event, which often falls under general investor communications. Since the content describes the event details where the company overview will be given, and it is not a formal report, 'IP' is the most relevant category for investor-facing content about strategy/overview.
2015-01-08 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release dated January 8, 2015, announcing that the CEO of Onxeo SA will be presenting the company, its progress, and outlook at the Biotech Showcase 2015 conference in San Francisco, which runs parallel to the JP Morgan Healthcare Conference. The text details the date, time, and location of the presentation and provides background information on the conference and the company. This type of announcement, detailing an upcoming presentation to investors at a major industry conference, strongly aligns with the definition of an Investor Presentation (IP), even though the document itself is a press release *about* the presentation, rather than the presentation slides themselves. However, given the context of financial filings, announcements regarding participation in major investor conferences where presentations are given are often categorized as Investor Presentation (IP) materials or related announcements. Since the document explicitly details the presentation event and context, 'IP' is the most fitting category among the choices, as it relates directly to investor outreach and strategy communication, distinct from a formal earnings release (ER) or a general regulatory filing (RNS). It is not a full transcript (CT) or a formal report (10-K, IR).
2015-01-08 French
Information relating to the total number of voting rights and shares making up the capital
Share Issue/Capital Change Classification · 1% confidence The document explicitly states its purpose in the title: 'Disclosure of total number of voting rights and number of shares in the capital at December 31, 2014'. It cites French commercial code and AMF regulations, which mandate such disclosures. The content is a table detailing the total outstanding shares and voting rights as of a specific date. This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing, often related to capital structure or shareholder information, but it does not fit perfectly into the defined categories like 10-K, ER, or DIV. It is a specific regulatory announcement concerning share capital and voting rights. Given the options, this is a specific regulatory disclosure. While it relates to capital, it is not a financing activity (CAP) or a share issue (SHA). It is a mandatory disclosure of the current share count. Since it is a specific regulatory disclosure that doesn't fit the primary financial reports (10-K, IR, ER), and it is not a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), the most appropriate fallback category for a specific, non-standard regulatory announcement is RNS (Regulatory Filings). However, let's re-evaluate the definitions. This is a disclosure of the total number of shares and voting rights, which is a fundamental piece of information often required periodically. It is not a general announcement of a report (RPA). It is a specific regulatory filing. If we look closely at the definitions, none perfectly capture 'Total Voting Rights Disclosure'. Given the context of French regulation and the nature of the data (share count disclosure), RNS is the best fit as a general regulatory filing that doesn't match the more specific financial or corporate action codes.
2015-01-07 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital au 31 décembre 2014" and explicitly references compliance with the French Commercial Code (Code de commerce) and the General Regulation of the AMF (Autorité des Marchés Financiers). It provides a table detailing the number of outstanding shares and voting rights as of a specific date (December 31, 2014). This type of mandatory disclosure regarding the total number of voting rights is a specific regulatory filing requirement, often related to capital structure updates or pre-AGM disclosures. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it deals specifically with the total number of voting rights and shares, it fits best under the category for official results from shareholder votes or related capital structure announcements. Given the options, this is a specific regulatory disclosure concerning voting rights/capital structure. While it is not the *results* of a vote (DVA), it is a mandatory disclosure related to the basis for voting rights. It is a specific regulatory announcement that doesn't fit perfectly into the main financial reports. However, the closest fit among the provided options for a mandatory disclosure about the total number of voting rights and shares, which is a prerequisite for shareholder meetings, is often grouped with governance or specific regulatory filings. Since it is a formal, dated announcement required by the regulator concerning the capital structure for voting purposes, and it is short (2101 chars), it could be considered a Regulatory Filing (RNS) or potentially related to DVA if it were results. Given the context of mandatory disclosure of voting rights count, and lacking a specific 'Voting Rights Basis' code, RNS (Regulatory Filings) is the most appropriate fallback for a specific, non-standard regulatory notice, although it is highly specific. Upon review, this is a standard monthly/quarterly disclosure of total voting rights, which is a regulatory requirement. It is not a general announcement (RPA) but a specific data filing. I will classify it as RNS as the best fit for a specific, non-core regulatory disclosure.
2015-01-07 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the "REALIZATION OF ITS SHARE CAPITAL INCREASE WITH SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS." It details the issuance of new shares, the resulting total share capital, and mentions the involvement of underwriters and regulatory filings (Prospectus filed with the AMF). This content directly relates to a corporate action involving the issuance of new equity and changes to the capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2014-12-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.